ImmunoCellular Therapeutics (OTCBB:IMUC) Thursday entered into an intellectual property licensing agreement with the University of Pittsburgh for the novel immunotherapeutic target EphA2.
EphA2 is a tyrosine kinase receptor that is highly expressed by ovarian cancer and other advanced and metastatic malignancies.
The financial terms of the agreement were not disclosed.
agreement grants a world-wide exclusive license to Pittsburgh
intellectual property for ovarian and pancreatic cancers; and a
world-wide non-exclusive license to Pittsburgh intellectual property for brain cancer.
said it will employ intellectual property in the development and
commercialization of ICT-140, a multivalent, dendritic cell-based
vaccine for the treatment of ovarian cancer.
ICT-140 is designed
to target cancer stem cells as well as daughter cells in ovarian cancer
by targeting multiple various antigens including EphA2, mesothelin,
Her-2/neu, IL-13Ra2 and several other undisclosed antigens.
data have indicated that EphA2, which is highly expressed by ovarian
cancer, holds significant promise as an immunotherapeutic target,
specifically for dendritic cell-based vaccines such as ICT-140,"
ImmunoCellular's president and CEO Dr. Manish Singh said.
The company intends to file an Investigative New Drug application for ICT-140 in the fourth quarter of this year.
"While further research is necessary to determine the therapeutic value EphA2, our decision to license it reflects our
to develop a novel vaccine that harnesses the patient’s native immune
system to precisely and comprehensively target multiple antigens
associated with ovarian cancer, a devastating disease that claims the
lives of over 15,000 women in the U.S. every year," Singh added.
is a Los Angeles-based clinical-stage company that is developing
immune-based therapies for the treatment of brain and other cancers.